NCT03530397: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated CNS metastatic disease or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03530397

Comments are closed.

Up ↑